Elevance Health posts Q3 2026 earnings beat and lifts 2026 adjusted EPS guidance to at least $29
+3 new sources since this summary was written
Elevance Health reported third‑quarter 2026 adjusted diluted earnings of $6.99 per share, well above analyst expectations of $4.70. Revenue reached $50.4 billion, up 0.7% year‑over‑year. The company raised its full‑year 2026 adjusted EPS floor to at least $29 and increased its operating cash‑flow target to at least $6.5 billion. CEO Gail K. Boudreaux said the beat reflected stronger execution across the portfolio and a favorable benefit‑expense ratio, while noting a 487‑thousand decline in medical membership year‑over‑year.
Why it matters
The higher EPS floor and cash‑flow guidance raise the earnings outlook for the rest of 2026, which could support the stock’s valuation. Investors will watch whether the non‑operating gains that contributed about $1.85 per share to the beat persist, as they affect the quality of the earnings beat.
Key facts
- 1Adjusted diluted EPS for Q3 2026 was $6.99 per share. stocktitan.net
- 2Revenue for Q3 2026 was $50.4 billion, up 0.7% from the prior year. stocktitan.net
- 3Full‑year 2026 adjusted EPS guidance was raised to at least $29 per share. stocktitan.net
- 4Full‑year 2026 operating cash‑flow guidance was raised to at least $6.5 billion. stocktitan.net
- 5Medical membership decreased by 487 thousand year‑over‑year to about 44.9 million members. stocktitan.net
Summary written by AlphAI AI Desk from 20 of 22 sources. Not investment advice. Figures are as stated by the linked sources.